Successful Subcutaneous Pancreatic Islet Transplantation Using an Angiogenic Growth Factor–Releasing Device

Kawakami, Yoshiyuki; Iwata, Hiroo; Gu, Yuan; Miyamoto, Masaaki; Murakami, Yoshinobu; Balamurugan, A. N.; Imamura, Masayuki; Inoue, Kazutomo

doi:10.1097/00006676-200111000-00007

Cited by 66 publications

(49 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonencapsulated islets may be injected into the liver (4,16,18,19,35,44,50,52) , kidney (5,14,15,16,17,24,27,28,32,34,35,42,46,47) , peritoneal cavity (11,35) , bone marrow (41) and subcutaneous tissue (22,48) . Ikebukuro et al (19) showed that islets and bone marrow cells, when injected into the liver using irradiation as immunosuppression, can increase the functionality of the cells for more than 365 days.…”

Section: Discussionmentioning

confidence: 99%

Islet transplantation in rodents: do encapsulated islets really work?

Souza

Chaib

Lacerda

et al. 2011

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Context -Diabetes mellitus type I affects around 240 million people in the world and only in the USA 7.8% of the population.It has been estimated that the costs of its complications account for 5% to 10% of the total healthcare spending around the world. According to World Health Organization, 300 million people are expected to develop diabetes mellitus by the year 2025. The pancreatic islet transplantation is expected to be less invasive than a pancreas transplant, which is currently the most commonly used approach. Objectives -To compare the encapsulated and free islet transplantation in rodents looking at sites of islet implantation, number of injected islets, viability and immunosuppression. Methods -A literature search was conducted using MEDLINE/PUBMED and SCIELO with terms about islet transplantation in the rodent from 2000 to 2010. We found 2,636 articles but only 56 articles from 2000 to 2010 were selected. Results -In these 56 articles used, 34% were encapsulated and 66% were nonencapsulated islets. Analyzing both types of islets transplantation, the majority of the encapsulated islets were implanted into the peritoneal cavity and the nonencapsulated islets into the liver, through the portal vein. In addition, the great advantage of the peritoneal cavity as the site of islet transplantation is its blood supply. Both vascular endothelial cells and vascular endothelial growth factor were used to stimulate angiogenesis of the islet grafts, increasing the vascularization rapidly after implantation. It also has been proven that there is influence of the capsules, since the larger the capsule more chances there are of central necrosis. In some articles, the use of immunosuppression demonstrated to increase the life expectancy of the graft. Conclusion -While significant progress has been made in the islets transplantation field, many obstacles remain to be overcome. Microencapsulation provides a means to transplant islets without immunosuppressive agents and may enable the performance of xenotransplantation. The use of alternative donor sources, fewer islets per capsule and the appropriate deployment location, such as the peritoneal cavity, may give a future perspective to the application of immunoprotective capsules and viability in clinical practice. A variety of strategies, such as genetic engineering, co-encapsulation, improvement in oxygen supply or the establishment of hypoxia resistance will also improve the islet transplantation performance. It remains to be determined which combination of strategies with encapsulation can fulfill the promise of establishing a simple and safe transplantation as a cure for diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Islet transplantation in rodents: do encapsulated islets really work?

Souza

Chaib

Lacerda

et al. 2011

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Maintained normoglycemia over the long termGu et al (2000)[85] PET mesh bag coated with PVAbFGF in agarose and hyaluronic acidDirect transplantationSubcutaneous tissue of dorsumInduced angiogenesis. Normalized blood glucose levels in the long termKawakami et al (2001)[86] Cationic lipid reagentVEGFDirect transplantationLeft kidney capsuleNormalized blood glucose level. Preserved transplanted islet cells with increasing vascularizationChae et al (2005)[43] R3V6 peptide micellessiRNA-iNOS, 17b-estradiolDirect transplantationLeft kidney capsuleImproved glycemic control.…”

Section: Islet Cell Transplantationmentioning

confidence: 99%

“…Islet cells coated with polyglycolic acid polymer have been shown to provide better glucose tolerance with more revascularization compared with naked islet cells when transplanted into the subcutaneous space of a mouse model of diabetes mellitus [82]. Other studies have reported that bio-artificial materials improved transplanted islet cell survival [83–86]. In these studies, a polyethylene terephthalate (PET) mesh bag that enclosed a collagen sponge and biodegradable gelatin microsphere containing basic fibroblast growth factor was transplanted into the subcutaneous space.…”

Section: Islet Cell Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus

Ookawara

Ishibashi

et al. 2017

Nano Reviews & Experiments

View full text Add to dashboard Cite

Gene therapy that targets the pancreas and intestines with delivery systems using nano-sized carriers such as viral and non-viral vectors could improve the control of blood glucose levels, resulting in an improved prognosis for patients with diabetes mellitus. Allogenic pancreatic islet cell transplantations using such delivery systems have been developed as therapeutic options for diabetes mellitus. This review focuses on transgenes and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus.

show abstract

“…In experimental studies, there are many descriptions of positive data on extrahepatic transplantation sites. The Kyoto and other groups [73] succeeded in achieving normoglycemia in diabetic mice by transplantation of encapsulated islets in muscle, subcutaneous tissue [58,[74][75][76] , renal subcapsule [77] and omentum [56] . These may be candidate transplantation sites in the near future because the loss of islets due to IBMIR, the risk of portal hypertension and portal vein thrombosis could be prevented.…”

Section: Ideal Transplantation Site For Encapsulated Isletsmentioning

confidence: 99%

Encapsulated islets transplantation: Past, present and future

Sakata

Sumi²,

Yoshimatsu³

et al. 2012

WJGP

View full text Add to dashboard Cite

Islet transplantation could become an ideal treatment for severe diabetes to prevent hypoglycemia shock and irreversible diabetic complications, once some of the major and unresolved obstacles are overcome, including limited donor supplies and side effects caused by permanent immunosuppressant use. Approximately 30 years ago, some groups succeeded in improving the blood glucose of diabetic animals by transplanting encapsulated islets with semi-permeable membranes consisting of polymer. A semi-permeable membrane protects both the inner islets from mechanical stress and the recipient's immune system (both cellular and humoral immunities), while allowing bidirectional diffusion of nutrients, oxygen, glucose, hormones and wastes, i.e., immune-isolation. This device, which enables immune-isolation, is called encapsulated islets or bio-artificial pancreas. Encapsulation with a semipermeable membrane can provide some advantages: (1) this device protects transplanted cells from the recipient's immunity even if the xenogeneic islets (from large animals such as pig) or insulin-producing cells are derived from cells that have the potential for differentiation (some kinds of stem cells). In other words, the encapsulation technique can resolve the problem of limited donor supplies; and (2) encapsulation can reduce or prevent chronic administration of immunosuppressants and, therefore, important side effects otherwise induced by immunosuppressants. And now, many novel encapsulated islet systems have been developed and are being prepared for testing in a clinical setting.

show abstract

Successful Subcutaneous Pancreatic Islet Transplantation Using an Angiogenic Growth Factor–Releasing Device

Abstract: This study provides evidence that the subcutaneous tissue is a promising site for pancreatic islet transplantation, which suggests the acceptability of this treatment for diabetic recipients.

Cited by 66 publications

References 22 publications

Islet transplantation in rodents: do encapsulated islets really work?

Islet transplantation in rodents: do encapsulated islets really work?

Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus

Encapsulated islets transplantation: Past, present and future

Contact Info

Product

Resources

About